Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

John Kuruvilla; Philippe Armand; Mehdi Hamadani; Justin Kline; Craig H. Moskowitz; David Avigan; Joshua D. Brody; Vincent Ribrag; Alex F. Herrera; Franck Morschhauser; Abraham Kanate; Pier Luigi Zinzani; Jacob Bitran; Herve Ghesquieres; Stephen J. Schuster; Mohammed Farooqui; Patricia Marinello; Nancy L. Bartlett

doi:10.1080/10428194.2022.2136956

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

John Kuruvilla, Philippe Armand, Mehdi Hamadani, Justin Kline, Craig H. Moskowitz, David Avigan, Joshua D. Brody, Vincent Ribrag, Alex F. Herrera, Franck Morschhauser, Abraham Kanate, Pier Luigi Zinzani, Jacob Bitran, Herve Ghesquieres, Stephen J. Schuster, Mohammed Farooqui, Patricia Marinello, Nancy L. Bartlett

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who were ineligible for or failed hematopoietic cell transplantation (HCT). Patients received pembrolizumab (cohort 4) or pembrolizumab plus lenalidomide (cohort 5). Primary end points were safety and objective response rate (ORR) per IWG 2007 criteria. Cohort 4 included 89 patients. ORR was 22% (19/86; 90% CI 15–31; 10 CR, nine PR); ORRs by disease type were 48% (10/21), 10% (2/20), 12% (5/41), and 50% (2/4), for PMBCL, FL, DLBCL, and ‘other’ NHL, respectively. Toxicity was as predicted. Cohort 5 included 19 patients. ORR was 39% (90% CI 20–61; four CR, three PR). Hematologic toxicities were the most common treatment-related AEs. In conclusion, pembrolizumab following HCT ineligibility/failure confirms prior experience in PMBCL but not with NHL subtypes in this study. Additional analyses in DLBCL may not be warranted.

Original language	English
Pages (from-to)	130-139
Number of pages	10
Journal	Leukemia and Lymphoma
Volume	64
Issue number	1
DOIs	https://doi.org/10.1080/10428194.2022.2136956
State	Published - 2023

Keywords

B-cell lymphoma
Non-Hodgkin lymphoma
PD-L1
pembrolizumab

Access to Document

10.1080/10428194.2022.2136956

Cite this

Kuruvilla, J., Armand, P., Hamadani, M., Kline, J., Moskowitz, C. H., Avigan, D., Brody, J. D., Ribrag, V., Herrera, A. F., Morschhauser, F., Kanate, A., Zinzani, P. L., Bitran, J., Ghesquieres, H., Schuster, S. J., Farooqui, M., Marinello, P., & Bartlett, N. L. (2023). Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. Leukemia and Lymphoma, 64(1), 130-139. https://doi.org/10.1080/10428194.2022.2136956

@article{4f87ba2dadd34d8f8efce8c6b42d9066,

title = "Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study",

abstract = "The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who were ineligible for or failed hematopoietic cell transplantation (HCT). Patients received pembrolizumab (cohort 4) or pembrolizumab plus lenalidomide (cohort 5). Primary end points were safety and objective response rate (ORR) per IWG 2007 criteria. Cohort 4 included 89 patients. ORR was 22% (19/86; 90% CI 15–31; 10 CR, nine PR); ORRs by disease type were 48% (10/21), 10% (2/20), 12% (5/41), and 50% (2/4), for PMBCL, FL, DLBCL, and {\textquoteleft}other{\textquoteright} NHL, respectively. Toxicity was as predicted. Cohort 5 included 19 patients. ORR was 39% (90% CI 20–61; four CR, three PR). Hematologic toxicities were the most common treatment-related AEs. In conclusion, pembrolizumab following HCT ineligibility/failure confirms prior experience in PMBCL but not with NHL subtypes in this study. Additional analyses in DLBCL may not be warranted.",

keywords = "B-cell lymphoma, Non-Hodgkin lymphoma, PD-L1, pembrolizumab",

author = "John Kuruvilla and Philippe Armand and Mehdi Hamadani and Justin Kline and Moskowitz, {Craig H.} and David Avigan and Brody, {Joshua D.} and Vincent Ribrag and Herrera, {Alex F.} and Franck Morschhauser and Abraham Kanate and Zinzani, {Pier Luigi} and Jacob Bitran and Herve Ghesquieres and Schuster, {Stephen J.} and Mohammed Farooqui and Patricia Marinello and Bartlett, {Nancy L.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2023",

doi = "10.1080/10428194.2022.2136956",

language = "English",

volume = "64",

pages = "130--139",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "1",

}

Kuruvilla, J, Armand, P, Hamadani, M, Kline, J, Moskowitz, CH, Avigan, D, Brody, JD, Ribrag, V, Herrera, AF, Morschhauser, F, Kanate, A, Zinzani, PL, Bitran, J, Ghesquieres, H, Schuster, SJ, Farooqui, M, Marinello, P & Bartlett, NL 2023, 'Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study', Leukemia and Lymphoma, vol. 64, no. 1, pp. 130-139. https://doi.org/10.1080/10428194.2022.2136956

TY - JOUR

T1 - Pembrolizumab for patients with non-Hodgkin lymphoma

T2 - phase 1b KEYNOTE-013 study

AU - Kuruvilla, John

AU - Armand, Philippe

AU - Hamadani, Mehdi

AU - Kline, Justin

AU - Moskowitz, Craig H.

AU - Avigan, David

AU - Brody, Joshua D.

AU - Ribrag, Vincent

AU - Herrera, Alex F.

AU - Morschhauser, Franck

AU - Kanate, Abraham

AU - Zinzani, Pier Luigi

AU - Bitran, Jacob

AU - Ghesquieres, Herve

AU - Schuster, Stephen J.

AU - Farooqui, Mohammed

AU - Marinello, Patricia

AU - Bartlett, Nancy L.

PY - 2023

Y1 - 2023

N2 - The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who were ineligible for or failed hematopoietic cell transplantation (HCT). Patients received pembrolizumab (cohort 4) or pembrolizumab plus lenalidomide (cohort 5). Primary end points were safety and objective response rate (ORR) per IWG 2007 criteria. Cohort 4 included 89 patients. ORR was 22% (19/86; 90% CI 15–31; 10 CR, nine PR); ORRs by disease type were 48% (10/21), 10% (2/20), 12% (5/41), and 50% (2/4), for PMBCL, FL, DLBCL, and ‘other’ NHL, respectively. Toxicity was as predicted. Cohort 5 included 19 patients. ORR was 39% (90% CI 20–61; four CR, three PR). Hematologic toxicities were the most common treatment-related AEs. In conclusion, pembrolizumab following HCT ineligibility/failure confirms prior experience in PMBCL but not with NHL subtypes in this study. Additional analyses in DLBCL may not be warranted.

AB - The multicohort phase 1b KEYNOTE-013 study (NCT01953692) evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL who were ineligible for or failed hematopoietic cell transplantation (HCT). Patients received pembrolizumab (cohort 4) or pembrolizumab plus lenalidomide (cohort 5). Primary end points were safety and objective response rate (ORR) per IWG 2007 criteria. Cohort 4 included 89 patients. ORR was 22% (19/86; 90% CI 15–31; 10 CR, nine PR); ORRs by disease type were 48% (10/21), 10% (2/20), 12% (5/41), and 50% (2/4), for PMBCL, FL, DLBCL, and ‘other’ NHL, respectively. Toxicity was as predicted. Cohort 5 included 19 patients. ORR was 39% (90% CI 20–61; four CR, three PR). Hematologic toxicities were the most common treatment-related AEs. In conclusion, pembrolizumab following HCT ineligibility/failure confirms prior experience in PMBCL but not with NHL subtypes in this study. Additional analyses in DLBCL may not be warranted.

KW - B-cell lymphoma

KW - Non-Hodgkin lymphoma

KW - PD-L1

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85142278083&partnerID=8YFLogxK

U2 - 10.1080/10428194.2022.2136956

DO - 10.1080/10428194.2022.2136956

M3 - Article

C2 - 36398795

AN - SCOPUS:85142278083

SN - 1042-8194

VL - 64

SP - 130

EP - 139

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 1

ER -

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this